ES301 / Elpiscience - LARVOL DELTA

Engineered DcR3-Fc Fusion Protein: A Robust Dual-Targeting Approach for TL1A and LIGHT in Autoimmune Diseases (ACR Convergence 2026) - " The engineered DcR3-Fc fusion protein, called ES301, exhibited superior developability and an extended pharmacokinetic profile compared to wild-type DcR3-Fc... In conclusion, we have engineered a novel DcR3-Fc fusion protein that simultaneously neutralizes both TL1A and LIGHT while preserving FASL signaling. This dual-targeting therapy demonstrated superior therapeutic efficacy and disease remission in a murine colitis model compared to single-agent treatments, highlighting its potential as a robust intervention for complex autoimmune diseases."

Gastroenterology • Gastrointestinal Disorder • Immunology • FASLG • TNFA • TNFRSF6B